Table 2 Clinical outcomes in ticagrelor discontinued group and ticagrelor continued group.
Group 1, n-237 | Group 2, n-72 | p value | |||
|---|---|---|---|---|---|
n | n% | n | n% | ||
Female | 44 | 18.60 | 7 | 9.70 | 0.077 |
Insulin-dependent diabetes mellitus | 13 | 5.50 | 10 | 13.90 | 0.017 |
Prior bleeding | 7 | 3.00 | 5 | 6.90 | 0.125 |
Hypertension | 113 | 47.70 | 46 | 63.90 | 0.016 |
Prior CAD | 101 | 42.60 | 31 | 43.10 | 0.947 |
Unstable angina | 101 | 42.60 | 24 | 33.30 | 0.16 |
NSTEMI | 25 | 10.50 | 12 | 16.70 | |
STEMI | 111 | 46.80 | 36 | 50.00 | |
EF ≤ 30% | 7 | 3.00 | 1 | 1.40 | 0.234 |
EF ≥ 55% | 133 | 56.10 | 48 | 66.70 | |
EF-30–45% | 44 | 18.60 | 14 | 19.40 | |
EF-45–55% | 53 | 22.40 | 9 | 12.50 | |
Left anterior descending artery (LAD) | 126 | 53.20 | 41 | 56.90 | 0.709 |
LCX-OM | 41 | 17.30 | 10 | 13.90 | |
RCA | 67 | 28.30 | 19 | 26.40 | |
Left main | 3 | 1.30 | 2 | 2.80 | |
Recurrent MI | 3 | 1.30 | 1 | 1.40 | 0.936 |
Re-intervention | 3 | 1.30 | 0 | 0.00 | |